Protagonist Therapeutics and its partner Johnson & Johnson have reported four phase III wins for their IL-23 receptor targeted peptide icotrokinra in plaque psoriasis, as well as a phase II ...
They may also be signalling molecules that act through interaction with specific receptors, as in peptide hormones and cytokines. A combinatorial mutagenesis optimization strategy (CoSMOS ...
Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for diabetes and obesity.
No other corporate actions details are available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback